Organoid-on-chip technology merges patient-derived organoids with microfluidic engineering to recreate human physiology and ...

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is one of the leading causes of dementia worldwide, and currently has no definitive cure. Although antibody-based therapies that ...

Urologic oncology has seen significant advances in precision therapy, with immunotherapy and organoid-based approaches at the forefront. Immunotherapy ...

Evolving patient needs are driving new drug development paradigms. For complex genetic diseases, traditional therapies often fall short. Gene therapies and nucleic acid medicines offer a way to repair ...

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / ...

The field of traditional medicine, with its deep historical roots, offers a multitude of natural compounds with potential therapeutic benefits. Lately, ...

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical ...

Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase 2 and Phase 3 clinical trials available CHICAGO, Nov. 21, 2025 (GLOBE NEWSWIRE ...